妊娠期血栓并发症:基于病例的证据综述
妊娠是雌激素驱动凝血系统改变、静脉淤滞及妊娠子宫压迫血流所致的血栓前状态,静脉血栓栓塞症(VTE)是妊娠期发病和死亡的主要原因之一。本综述通过三个病例探讨妊娠期VTE诊断、初始抗凝、分娩及产后管理、遗传性与获得性易栓症检测、产科抗磷脂综合征管理及产后血栓预防的风险评估与持续时间剂量,指出高质量数据进展、知识缺口与专家意见差异,强调多学科讨论与协作高质量试验的重要性。
要点
- 妊娠期VTE诊断、初始抗凝及围分娩期管理需结合病例个体化决策。
- 复发性流产患者应评估遗传性与获得性易栓症,并管理产科抗磷脂综合征。
- 产后VTE风险评估及血栓预防的持续时间与剂量需依据证据与专家意见。
核心结论
- 妊娠期血栓并发症的临床决策需综合近期高质量数据、知识缺口与专家意见差异,多学科讨论和团队协作是优化安全诊疗的关键。
- 临床医生应优先开展协作性高质量试验和前瞻性临床管理研究,以更好地理解和定义该人群的最佳实践。
研究设计与样本
- 本文为基于病例的综述,通过三个妊娠期血栓并发症病例探讨相关证据。
主要发现
- 第一例概述妊娠期VTE诊断、初始抗凝管理、分娩及产后管理以及后续长期抗凝治疗。
- 第二例探讨复发性流产背景下遗传性和获得性易栓症检测及产科抗磷脂综合征的管理。
- 第三例回顾妊娠期及产后VTE风险评估与预防,以及产后血栓预防的持续时间和剂量。
临床怎么用
- 妊娠期VTE的诊断、初始抗凝、围分娩期及产后管理可参考本综述病例所示证据进行决策。
- 复发性流产患者可进行遗传性和获得性易栓症检测,并管理产科抗磷脂综合征。
- 妊娠期及产后应进行VTE风险评估与预防,产后血栓预防需考虑持续时间和剂量。
- 多学科讨论和团队协作应作为优化安全诊疗的关键。
局限性
- 本综述指出当前存在知识缺口和专家意见差异。
- 本综述指出需要协作性高质量试验和前瞻性临床管理研究以定义最佳实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pregnancy is a prothrombotic state due to an estrogen-driven shift in the coagulation system, increased venous stasis, and external restriction of blood flow caused by the gravid uterus. Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in pregnancy. Preventing, recognizing, and treating thrombosis in pregnancy, as well as the postpartum period, often challenges decision making in the clinical setting. In early pregnancy, guidance with respects to thrombophilia testing and anticoagulation in increasing the likelihood of live birth among patients with recurrent miscarriages is evolving. This review explores emerging data that support clinical decision making in thrombosis care in women with common thrombotic complications in pregnancy. The first case outlines VTE diagnosis in pregnancy, initial anticoagulation management, management around delivery and postpartum, and subsequent long-term anticoagulation treatment. The second case examines testing for inherited and acquired thrombophilia in the setting of recurrent miscarriage and the management of obstetric antiphospholipid syndrome. Lastly, the third case reviews VTE risk assessment and prevention in pregnancy and the postpartum period, as well as duration and dose of postpartum thromboprophylaxis. Review of these common clinical scenarios surrounding thrombotic complications in pregnancy demonstrates recent advances in high-quality data, current gaps in knowledge, and variation in expert opinion. Ultimately, multidisciplinary discussion and teamwork remain key to optimal, safe care. Clinicians must prioritize collaborative, high-quality trials and prospective clinical management studies to better understand and define best practice in this population.
引用
- Merz LE, Bassa B, Ní Áinle F, et al. Thrombotic complications in pregnancy: a case-based review of the evidence. J Thromb Haemost. 2024. PMID: 39395543. doi:10.1016/j.jtha.2024.09.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。